BiotechTube
Home/Adecto Pharmaceuticals/John Tagliamonte, MBA
JT

John Tagliamonte, MBA

Corporate Development Lead

Adecto Pharmaceuticals

Therapeutic Areas

Oncology

Adecto Pharmaceuticals Pipeline

DrugIndicationPhase
Anti-ADAM8 mAbADAM8-positive cancers (e.g., Colorectal, Breast, Kidney)Pre-clinical

Leadership Team at Adecto Pharmaceuticals

ND
Nora D. Mineva, PhD
Co-founder, CEO & Chief Scientific Officer
GE
Gail E. Sonenshein, PhD
Co-founder & President
SP
Stefania Pianetti, PhD
Head, Preclinical & Translational Development
View full Adecto Pharmaceuticals profile